IMUX News and Press, Immunic Inc. From 02/13/26

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company PR Newswire – Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expe...

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis PR Newswire – Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chro...

Immunic Highlights 2025 Accomplishments and Upcoming Milestones PR Newswire – Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 – – Phase 2 CALLIPER Data Showed...

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December PR Newswire NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for...

2025-11-13 06:35:18 ET More on Immunic Immunic, Inc. (IMUX) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 - Slideshow Immunic, Inc. (IMUX) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow Seeking Alpha&#...

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire – Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41 st Congress of ECTRIMS  – – Phase 2 CALL...

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

Immunic to Participate in Industry and Investor Conferences in November PR Newswire NEW YORK , Oct. 29, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therap...

Immunic to Participate in Scientific and Investor Conferences in October PR Newswire NEW YORK , Oct. 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule t...